New dual-immunotherapy combo tested in advanced cancers

NCT ID NCT05858736

First seen Apr 10, 2026 · Last updated May 07, 2026 · Updated 5 times

Summary

This early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for side effects. About 18 adults with various cancers like melanoma, lung, or ovarian cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cancer Research SA

    Adelaide, South Australia, 5000, Australia

  • Mater Misericordiae Ltd.

    Brisbane, Queensland, 4006, Australia

  • Southern Oncology Clinical Research Unit

    Bedford Park, South Australia, 5042, Australia

  • St. Vincent's Private Hospital

    Darlinghurst, New South Wales, 2010, Australia

  • Tasman Oncology Research

    Southport, Queensland, 4120, Australia

Conditions

Explore the condition pages connected to this study.